Anhui Huaren Health Pharmaceutical Co. Ltd. Cl A
Anhui Huaren Health Pharmaceutical Co., Ltd. operates in the medical and healthcare industry. It offers products for oral and throat, nourishing, heat-clearing, respiratory system, and gynecology, as well as provides vitamins and minerals, and detoxifying products. In addition, it provides supplements, and nutrition and health products. Anhui Huaren Health Pharmaceutical Co., Ltd. was founded in … Read more
Anhui Huaren Health Pharmaceutical Co. Ltd. Cl A (301408) - Total Liabilities
Latest total liabilities as of June 2025: CN¥3.14 Billion CNY
Based on the latest financial reports, Anhui Huaren Health Pharmaceutical Co. Ltd. Cl A (301408) has total liabilities worth CN¥3.14 Billion CNY as of June 2025.
Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities.
Anhui Huaren Health Pharmaceutical Co. Ltd. Cl A - Total Liabilities Trend (2021–2024)
This chart illustrates how Anhui Huaren Health Pharmaceutical Co. Ltd. Cl A's total liabilities have evolved over time, based on quarterly financial data. Explore and compare other companies by total liabilities.
Anhui Huaren Health Pharmaceutical Co. Ltd. Cl A Competitors by Total Liabilities
The table below lists competitors of Anhui Huaren Health Pharmaceutical Co. Ltd. Cl A ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Cicor Technologies Ltd
SW:CICN
|
Switzerland | CHF347.12 Million |
|
Qinghai Huzhu Barley Wine Co Ltd
SHE:002646
|
China | CN¥446.82 Million |
|
SNDL Inc.
NASDAQ:SNDL
|
USA | $218.77 Million |
|
Audinate Group Limited
PINK:AUDGF
|
USA | $17.09 Million |
|
SWS Hemodialysis Care Co. Ltd. A
SHG:688410
|
China | CN¥349.56 Million |
|
Berto Acquisition Corp. Ordinary Shares
NASDAQ:TACO
|
USA | $11.94 Million |
Liability Composition Analysis (2021–2024)
This chart breaks down Anhui Huaren Health Pharmaceutical Co. Ltd. Cl A's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 1.06 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 1.53 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.60 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Anhui Huaren Health Pharmaceutical Co. Ltd. Cl A's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Anhui Huaren Health Pharmaceutical Co. Ltd. Cl A (2021–2024)
The table below shows the annual total liabilities of Anhui Huaren Health Pharmaceutical Co. Ltd. Cl A from 2021 to 2024.
| Year | Total Liabilities | Change |
|---|---|---|
| 2024-12-31 | CN¥2.77 Billion | +5.03% |
| 2023-12-31 | CN¥2.64 Billion | +61.75% |
| 2022-12-31 | CN¥1.63 Billion | +37.37% |
| 2021-12-31 | CN¥1.19 Billion | -- |